Direct supply of high-purity Active Pharmaceutical Ingredients meeting strict USP/EP/Ph. Eur. specifications for hospital injectables and critical medical formulations in South America.
The Brazilian pharmaceutical market represents the largest healthcare ecosystem in Latin America and ranks among the top ten global markets by revenue. Driven by the expanding coverage of the Unified Health System (Sistema Único de Saúde - SUS), an aging population demographic, and rising chronic disease incidence, the demand for high-quality Active Pharmaceutical Ingredients (APIs) has grown exponentially. However, Brazil remains structurally dependent on foreign raw materials, importing over 90% of its API volume for national drug formulation.
For Brazilian pharmaceutical manufacturers (Laboratórios Farmacêuticos), sourcing APIs is not merely a matter of commercial procurement; it is a complex exercise in regulatory compliance under the strict oversight of the Agência Nacional de Vigilância Sanitária (ANVISA). Recent regulatory frameworks, specifically RDC 359/2020 (establishing the Active Pharmaceutical Ingredient Dossier - DIFA) and RDC 658/2021 (aligning Brazilian cGMP with international PIC/S standards), have raised the technical threshold for imported APIs. Global API manufacturers must now demonstrate full process validation, complete impurity profiling, and robust control over nitrosamines and residual solvents to secure the Carta de Adequação de Dossiê de Insumo Farmacêutico Ativo (CADIFA).
Gentolex Group stands at the forefront of this evolving ecosystem, providing seamless supply chain solutions, custom peptide synthesis, and high-purity small molecule APIs engineered specifically to pass ANVISA's rigorous technical evaluations. By establishing robust regulatory documentation and transparent supply pathways, we empower Brazilian pharmaceutical companies to accelerate product registration, optimize production yields, and guarantee drug safety for millions of patients across Brazil.
Navigating ANVISA's DIFA procedure requires deep technical mastery of analytical method validation, structural characterization, stability study protocols under Zone IVb conditions (30°C / 75% RH for Brazil), and comprehensive impurity profiling (including elemental impurities as per ICH Q3D and nitrosamines risk evaluation per ICH M7). Our regulatory team provides turnkey CTD-format dossiers to fast-track CADIFA issuance.
Critical care medicine in Brazil faces mounting challenges from antimicrobial resistance (AMR). We specialize in systemic antifungal and antibacterial APIs such as Caspofungin, Daptomycin, Micafungin, and Vancomycin, alongside custom therapeutic peptides. Our advanced fermentation and solid-phase peptide synthesis (SPPS) technologies ensure batch-to-batch consistency and exceptional purity (>99.0%).
The Brazilian pharmaceutical manufacturing landscape is anchored in key industrial clusters across the states of São Paulo (Campinas, Ribeirão Preto, Greater São Paulo), Goiás (Anápolis hub), Minas Gerais, and Rio de Janeiro. Local drug producers serve two distinct market channels: the private retail market driven by generic (Genéricos) and branded generic (Similares) formulations, and the public health system (SUS) driven by centralized federal procurements and Partnerships for Productive Development (Parcerias para o Desenvolvimento Produtivo - PDP).
To successfully integrate into local Brazilian formulation lines, API suppliers must address unique pharmaceutical engineering and formulation requirements:
Formulation Synergy: Tailored API physical attributes—such as particle size distribution (PSD) optimization via micronization, polymorph consistency, bulk density, and powder flowability—are critical for direct compression tablets, hard gelatin capsules, and stable lyophilized injectable vials.
Mitigating geopolitical risk, optimizing freight logistics to Latin America, and ensuring end-to-end traceably compliant chemical synthesis.
Operating a massive 250,000 square meter standardized production base, Gentolex maintains complete backward integration into key chemical intermediates. This protects Brazilian clients against raw material price volatility and guarantees multi-ton annual capacity for commercial supply agreements.
Biologics and temperature-sensitive APIs (e.g., lyophilized peptides, Caspofungin, Daptomycin) require uncompromised cold-chain maintenance. We utilize validated thermal packaging (2°C–8°C and -20°C conditions) with real-time IoT temperature monitoring across direct air corridors to Guarulhos (GRU) and Viracopos (VCP) airports.
Navigating Brazilian import regulations (SISCOMEX and ANVISA import licensing under Deferimento de LI) can lead to customs delays. Gentolex partners with experienced Brazilian customs brokers to streamline clearing procedures, providing pre-inspected analytical certificates and documentation.
As the pharmaceutical industry transitions toward sustainable manufacturing and complex modalities, API synthesis methods must evolve. Gentolex is implementing green chemistry initiatives and continuous flow technology across our primary manufacturing suites:
For custom long-chain peptides and therapeutic peptide APIs (such as GLP-1 analogues, Semax, BPC-157, and SS-31), hybrid synthesis combines the speed of SPPS with the scalability of LPPS. This strategy drastically reduces organic solvent consumption (acetonitrile, DMF) while boosting overall yield and crude purity beyond 95% before preparative HPLC purification.
Moving from traditional batch reactors to continuous micro-reactors allows precise control over reaction kinetics, temperature, and stoichiometry. This minimizes unwanted side-reactions, eliminates dangerous thermal runaways in exothermic reactions, and guarantees ultra-low impurity levels aligned with ICH Q3A/B guidelines.
Comprehensive B2B solutions designed for global biopharmaceutical enterprises, contract development and manufacturing organizations (CDMOs), and local Brazilian drug formulators.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Dedicated R&D centers equipped with ultra-performance liquid chromatography (UPLC), LC-MS/MS, NMR, and XRPD to support route verification, polymorph screening, and impurity isolation.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Our commitment to E-E-A-T (Experience, Expertise, Authoritativeness, and Trustworthiness) underpins every batch certificate, regulatory filing, and client collaboration we execute globally.
Explore our scientific updates on active pharmaceutical ingredients, research-grade synthetic peptides, and neuroactive compound synthesis.
Expert answers regarding ANVISA compliance, CADIFA registration, logistics, and quality assurance for Brazilian procurement managers.
Browse our extensive catalogue of synthetic APIs, metabolic regulators, and advanced amino acid derivatives available for immediate export to Brazil.
Accelerate your ANVISA approval timeline, secure reliable cGMP raw material supplies, and access competitive direct-from-factory pricing for your pharmaceutical formulations.
Send Inquiry Now
